Candesartan-induced cholestatic hepatitis: a case report
Author(s) -
Benito Hermida,
Marta Izquierdo Romero,
Rosa García López
Publication year - 2020
Publication title -
revista española de enfermedades digestivas
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6988/2020
Subject(s) - candesartan , cholestatic hepatitis , medicine , hepatitis , cardiology , receptor , angiotensin ii
We present the case of a 55-year-old male that was admitted to our hospital for cholestatic hepatitis. Other causes of hepatitis were excluded with imaging, laboratory and serologic tests. A liver biopsy was performed, which was compatible with toxicity-induced hepatitis. Re-assessing the patient, he mentioned the start of treatment with candesartan cilexetil 3 weeks prior to the onset of the symptoms. Candesartan was withdrawn, with a progressive improvement in cholestasis and complete normalization of liver biochemistry at 6 months. The patient was diagnosed with candesartan-induced cholestatic hepatitis, probable according to CIOMS/RUCAM scale.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom